LUNAPHORE-TECHNOLOGIES
14.1.2021 14:02:40 CET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/
The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.
The new Lunaphore SAB will be comprised of the following members:
- Prof. Paolo A. Ascierto, MD
Dr. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC), President of the Fondazione Melanoma Onlus, and of Campania Society of ImmunoTherapy of Cancer (SCITO). He is an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and Associate Editor of Journal of ImmunoTherapy of Cancer. He has been the Principal Investigator in over 100 clinical trials and is the author of more than 450 publications in peer-reviewed journals.
- Dr. Jérôme Galon
Dr. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. Dr. Galon defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. This scientific contribution was acknowledged by many awards such as the William B. Coley Award, the Award from the National Academy of Science, from the National Academy of Medicine, and European Inventor Award 2019. He is the co-founder of HalioDx and the Chairman of its Scientific Council.
“I am excited to have such great experts in I-O join our SAB,” said Dr. Dupouy, CTO at Lunaphore. “Their expertise in the field will be key to focus our research efforts on the most promising I-O applications, as well as to expand our scientific collaborations worldwide.”
"The key for the immune responsiveness is in the tumor microenvironment,” noted Dr. Ascierto. “Lunaphore has a technology which can potentially make such evaluation easier and greatly contribute to the research field of immunotherapy."
“Lunaphore is developing rapid automated staining instruments based on an innovative microfluidic technology with great potential for multiple research applications,” Dr. Galon said. “I look forward to the next generation hyper-plex immunofluorescence instruments.”
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meraki Capital Launches Tessero Across Six European Markets Following Landmark Hays Acquisition1.9.2026 22:36:00 CEST | Press release
Meraki Capital has launched Tessero,a new European specialist recruitment group created from the six former Hays plc businesses it acquired earlier this summer. Launching simultaneously across Sweden, Denmark, Hungary, Romania, Luxembourg and Czechia, Tessero brings six established recruitment businesses together under one independent European brand, creating an international platform with experienced teams, existing clients and active candidate networks from day one. The launch follows one of the most significant transactions in Meraki Capital’s history and the completion of a major transition programme across all six countries within weeks of the acquisition. 130 employees will now operate under the Tessero brand, with established country leadership teams remaining in place and continuing to lead their respective markets. Gary Elden OBE, CEO of Meraki Capital and Director of Tessero, said: “Tessero launches with something that normally takes years to build: established businesses, ex
SBC Medical to Participate in Several Upcoming Investor Conferences in September 20261.9.2026 19:35:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in September 2026. SBC Medical will conduct presentations and one-on-one meetings with institutional investors. Below is a summary of the Company’s scheduled participation in upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference Date: September 14 2026 Format: In-person (NY) Registration: https://my.ct.events/register.aspx?meid=cff43623-9e9f-45d4-bbc3-ee19e9c372c1&rpid=a667ca45-171e-4306-98eb-c466e8b7e6c1 ArcStone Kingswood Growth Summit 2026 Date: September 16 2026 Format: In-person (Toronto) Registration:https://www.meetmax.com/sched/event_144037/investor_reg_new.html?attendee_role_id=ARCSTONE_ATTENDEE CLSA 33rd Investors’ Forum 2026 Date: September 21, 2026 Format: In-person (Hong K
Crimson Moon Available Now, Bringing Heavy-Metal Gothic Action to Solo and Co-op Players on PC, PlayStation 5, and Xbox Series X|S1.9.2026 19:00:00 CEST | Press release
ProbablyMonsters’ action-adventure RPG offers blood-soaked combat, monstrous showdowns, and deep replay value for $19.99 USD ProbablyMonsters, an independent video game company creating original AA games with AAA sensibilities, today launched Crimson Moon on PC via Steam and Epic Game Store, PlayStation 5, and Xbox Series X|S for $19.99 USD. A $29.99 USD Deluxe Edition is also available and includes an exclusive armor set, weapon cosmetic, and upcoming game expansion. Watch the official Crimson Moon launch trailer on YouTube to see the game’s gothic heavy-metal power fantasy, crafted for both solo and co-op players, in action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901064893/en/ Crimson Moon is a gothic high renaissance action-adventure RPG built around intense, replayable missions that blend brutal precision with deep character progression. Players take on the role of the Nephilim, powerful human-angel hybrids bo
Rigaku Launches CT Lab HR160 High-Resolution X-ray CT System1.9.2026 17:00:00 CEST | Press release
- Developed in collaboration with Excillum for battery, semiconductor devices, and advanced materials analysis - Rigaku Corporation, a global solutions partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), today announced the launch of the CT Lab HR160, a high-resolution X-ray computed tomography (CT) system for battery, semiconductor devices, electronic components, and advanced materials analysis. The system is developed in collaboration with Excillum AB, the global source for X-ray innovation (Headquarters: Stockholm, Sweden; CEO: David Lindblom; “Excillum”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901074099/en/ Photo: CT Lab HR160 High-Resolution X-ray CT System CT Lab HR160 combines Rigaku’s X-ray CT imaging expertise with Excillum’s NanoTube N3 X-ray source. Operating at up to 160 kV to support a wide r
GigaDevice Joins the Zephyr® Project to Foster Global Open-Source Ecosystem1.9.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially joined the Zephyr® Project, one of the world’s leading open-source real-time operating systems (RTOS). Hosted by the Linux Foundation®, the Zephyr® Project welcomes GigaDevice as a Silver Member, making GigaDevice a dual Silver Member of both the Zephyr® Project and the Linux Foundation. Leveraging its comprehensive GD32 MCU portfolio, GigaDevice will actively participate in the Zephyr® community, promoting deeper integration between its MCU technologies and the global open-source RTOS ecosystem. This will provide customers and developers in industrial, IoT, consumer electronics, and other fields with a more open, standardized, and efficient embedded development environment, while continuing to contribute to the growth of the global embedded open ecosystem and broader access to technology. With the continued evolution of the Internet of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom